299 related articles for article (PubMed ID: 27115835)
1. Rapid Discovery and Structure-Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase.
Fraser C; Dawson JC; Dowling R; Houston DR; Weiss JT; Munro AF; Muir M; Harrington L; Webster SP; Frame MC; Brunton VG; Patton EE; Carragher NO; Unciti-Broceta A
J Med Chem; 2016 May; 59(10):4697-710. PubMed ID: 27115835
[TBL] [Abstract][Full Text] [Related]
2. Discovery of 2-((3-Amino-4-methylphenyl)amino)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-4-(methylamino)pyrimidine-5-carboxamide (CHMFL-ABL-053) as a Potent, Selective, and Orally Available BCR-ABL/SRC/p38 Kinase Inhibitor for Chronic Myeloid Leukemia.
Liang X; Liu X; Wang B; Zou F; Wang A; Qi S; Chen C; Zhao Z; Wang W; Qi Z; Lv F; Hu Z; Wang L; Zhang S; Liu Q; Liu J
J Med Chem; 2016 Mar; 59(5):1984-2004. PubMed ID: 26789553
[TBL] [Abstract][Full Text] [Related]
3. Development of 2'-aminospiro [pyrano[3,2-c]quinoline]-3'-carbonitrile derivatives as non-ATP competitive Src kinase inhibitors that suppress breast cancer cell migration and proliferation.
Ramadan M; A M M Elshaier Y; Aly AA; Abdel-Aziz M; Fathy HM; Brown AB; Pridgen JR; Dalby KN; Kaoud TS
Bioorg Chem; 2021 Nov; 116():105344. PubMed ID: 34598088
[TBL] [Abstract][Full Text] [Related]
4. 2-Hydroxypropyl-β-cyclodextrin strongly improves water solubility and anti-proliferative activity of pyrazolo[3,4-d]pyrimidines Src-Abl dual inhibitors.
Dreassi E; Zizzari AT; Mori M; Filippi I; Belfiore A; Naldini A; Carraro F; Santucci A; Schenone S; Botta M
Eur J Med Chem; 2010 Dec; 45(12):5958-64. PubMed ID: 20970221
[TBL] [Abstract][Full Text] [Related]
5. Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
Guo Y; Liu Y; Hu N; Yu D; Zhou C; Shi G; Zhang B; Wei M; Liu J; Luo L; Tang Z; Song H; Guo Y; Liu X; Su D; Zhang S; Song X; Zhou X; Hong Y; Chen S; Cheng Z; Young S; Wei Q; Wang H; Wang Q; Lv L; Wang F; Xu H; Sun H; Xing H; Li N; Zhang W; Wang Z; Liu G; Sun Z; Zhou D; Li W; Liu L; Wang L; Wang Z
J Med Chem; 2019 Sep; 62(17):7923-7940. PubMed ID: 31381333
[TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of novel 3-sulfonylpyrazol-4-amino pyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors.
Zhang P; Dong J; Zhong B; Zhang D; Yuan H; Jin C; Xu X; Li H; Zhou Y; Liang Z; Ji M; Xu T; Song G; Zhang L; Chen G; Meng X; Sun D; Shih J; Zhang R; Hou G; Wang C; Jin Y; Yang Q
Bioorg Med Chem Lett; 2016 Apr; 26(8):1910-8. PubMed ID: 26979157
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, EGFR Inhibition and Anti-cancer Activity of New 3,6-dimethyl-1-phenyl-4-(substituted-methoxy)pyrazolo[3,4-d] pyrimidine Derivatives.
Bakr RB; Mehany ABM; Abdellatif KRA
Anticancer Agents Med Chem; 2017; 17(10):1389-1400. PubMed ID: 28270084
[TBL] [Abstract][Full Text] [Related]
8. Novel heterocyclic-fused pyrimidine derivatives: synthesis, molecular modeling and pharmacological screening.
Arafa RK; Nour MS; El-Sayed NA
Eur J Med Chem; 2013 Nov; 69():498-507. PubMed ID: 24090920
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, design, and antiproliferative evaluation of 6-(N-Substituted-methyl)pyrazolo[3,4-d]pyrimidines as the potent anti-leukemia agents.
Chung CY; Li SM; Zeng WZ; Uramaru N; Huang GJ; Juang SH; Wong FF
Bioorg Chem; 2024 Jul; 148():107424. PubMed ID: 38728908
[TBL] [Abstract][Full Text] [Related]
10. Efficient optimization of pyrazolo[3,4-d]pyrimidines derivatives as c-Src kinase inhibitors in neuroblastoma treatment.
Molinari A; Fallacara AL; Di Maria S; Zamperini C; Poggialini F; Musumeci F; Schenone S; Angelucci A; Colapietro A; Crespan E; Kissova M; Maga G; Botta M
Bioorg Med Chem Lett; 2018 Nov; 28(21):3454-3457. PubMed ID: 30262428
[TBL] [Abstract][Full Text] [Related]
11. From Lead to Drug Candidate: Optimization of 3-(Phenylethynyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Derivatives as Agents for the Treatment of Triple Negative Breast Cancer.
Zhang CH; Chen K; Jiao Y; Li LL; Li YP; Zhang RJ; Zheng MW; Zhong L; Huang SZ; Song CL; Lin WT; Yang J; Xiang R; Peng B; Han JH; Lu GW; Wei YQ; Yang SY
J Med Chem; 2016 Nov; 59(21):9788-9805. PubMed ID: 27739679
[TBL] [Abstract][Full Text] [Related]
12. Pyrazolo[3,4-d]pyrimidines endowed with antiproliferative activity on ductal infiltrating carcinoma cells.
Carraro F; Pucci A; Naldini A; Schenone S; Bruno O; Ranise A; Bondavalli F; Brullo C; Fossa P; Menozzi G; Mosti L; Manetti F; Botta M
J Med Chem; 2004 Mar; 47(7):1595-8. PubMed ID: 15027847
[TBL] [Abstract][Full Text] [Related]
13. Identification of a new family of pyrazolo[3,4-d]pyrimidine derivatives as multitarget Fyn-Blk-Lyn inhibitors active on B- and T-lymphoma cell lines.
Fallacara AL; Passannanti R; Mori M; Iovenitti G; Musumeci F; Greco C; Crespan E; Kissova M; Maga G; Tarantelli C; Spriano F; Gaudio E; Bertoni F; Botta M; Schenone S
Eur J Med Chem; 2019 Nov; 181():111545. PubMed ID: 31400706
[TBL] [Abstract][Full Text] [Related]
14. Tyrosine kinase inhibition effects of novel Pyrazolo[1,5-a]pyrimidines and Pyrido[2,3-d]pyrimidines ligand: Synthesis, biological screening and molecular modeling studies.
El Sayed MT; Hussein HAR; Elebiary NM; Hassan GS; Elmessery SM; Elsheakh AR; Nayel M; Abdel-Aziz HA
Bioorg Chem; 2018 Aug; 78():312-323. PubMed ID: 29625271
[TBL] [Abstract][Full Text] [Related]
15. Novel Pyrazolo[3,4-d]pyrimidines as Potential Cytotoxic Agents: Design, Synthesis, Molecular Docking and CDK2 Inhibition.
Maher M; Kassab AE; Zaher AF; Mahmoud Z
Anticancer Agents Med Chem; 2019; 19(11):1368-1381. PubMed ID: 31038080
[TBL] [Abstract][Full Text] [Related]
16. Combining X-ray crystallography and molecular modeling toward the optimization of pyrazolo[3,4-d]pyrimidines as potent c-Src inhibitors active in vivo against neuroblastoma.
Tintori C; Fallacara AL; Radi M; Zamperini C; Dreassi E; Crespan E; Maga G; Schenone S; Musumeci F; Brullo C; Richters A; Gasparrini F; Angelucci A; Festuccia C; Delle Monache S; Rauh D; Botta M
J Med Chem; 2015 Jan; 58(1):347-61. PubMed ID: 25469771
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and in vitro antiproliferative and kinase inhibitory effects of pyrimidinylpyrazole derivatives terminating with arylsulfonamido or cyclic sulfamide substituents.
Gamal El-Din MM; El-Gamal MI; Abdel-Maksoud MS; Yoo KH; Baek D; Choi J; Lee H; Oh CH
J Enzyme Inhib Med Chem; 2016; 31(sup2):111-122. PubMed ID: 27255180
[TBL] [Abstract][Full Text] [Related]
18. Novel pyrazolo[3,4-d]pyrimidines as dual Src-Abl inhibitors active against mutant form of Abl and the leukemia K-562 cell line.
El-Moghazy SM; George RF; Osman EEA; Elbatrawy AA; Kissova M; Colombo A; Crespan E; Maga G
Eur J Med Chem; 2016 Nov; 123():1-13. PubMed ID: 27474918
[TBL] [Abstract][Full Text] [Related]
19. Discovery and Optimization of a Novel 2
Wei Y; Tang Y; Zhou Y; Yang Y; Cui Y; Wang X; Wang Y; Liu Y; Liu N; Wang Q; Li C; Ruan H; Zhou H; Wei M; Yang G; Yang C
J Med Chem; 2021 Jul; 64(13):9078-9099. PubMed ID: 34129329
[TBL] [Abstract][Full Text] [Related]
20. A Conformation Selective Mode of Inhibiting SRC Improves Drug Efficacy and Tolerability.
Temps C; Lietha D; Webb ER; Li XF; Dawson JC; Muir M; Macleod KG; Valero T; Munro AF; Contreras-Montoya R; Luque-Ortega JR; Fraser C; Beetham H; Schoenherr C; Lopalco M; Arends MJ; Frame MC; Qian BZ; Brunton VG; Carragher NO; Unciti-Broceta A
Cancer Res; 2021 Nov; 81(21):5438-5450. PubMed ID: 34417202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
